依达拉奉治疗重型颅脑损伤临床疗效分析

Analysis of the clinical efficacy of edaravone on severe cranicerebral injuries

目的探讨依达拉奉治疗重型颅脑损伤临床疗效及安全性。方法将68例重型颅脑损伤患者分为观察组和对照组各34例,对照组给予止血、脱水、神经营养药物等常规治疗,观察组在此基础上加用依达拉奉治疗,观察两组患者治疗前后脑水肿程度变化情况、意识恢复情况及不良反应情况。结果观察组治疗7d及14d后脑水肿减小幅度均高于对照组(P<0.05);观察组治疗7d及14d后GCS评分均高于对照组(P<0.05),观察组治疗14d后APACHE-Ⅱ评分低于对照组(P<0.05)。结论依达拉奉用于治疗重型颅脑损伤能有效的促进患者脑神经功能恢复,减轻脑水肿,安全有效,值得推广。

Objective To investigate the clinical efficacy and safety of Edaravone on severe craniocerebral injuries. Methods 68 cases of severe craniocerebral injury were divided into the observation group and the control group, each with 34 cases. The control group was treated with routine therapy of hemostasis, dehydration and neurotrophic drugs, while the observation group was treated with Edaravone additionally. Observations were carried out about changes of hydrocephalus levels, conscientiousness recovery and adverse effects of both groups before and after treatment. Results As for the observation group, its ranges for the decrease of hydrocephalus were lower than those of the control group 7d and 14d after the treatment（P 〈 0.05）. Its GCS ratings were higher than those of the control group 7d and 14d after the treatment （P〈0.05）. Its APACHE-Ⅱ ratings were lower than those of the control group 14d after the treatment（P 〈 0.05）. Conclusion With effective promotion of the recovery of brain neural functions, decrease of hydrocephalus safely, Edaravone is worth promotion in the treatment of severe craniocerebral injuries.